Transaction adds TYMLOS® to portfolio alongside NUZYRA® and XHANCE® and creates a diversified portfolio expected to generate nearly $1 billion in ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market Acquisition advances Paratek’s ...

The world needs new antibiotics, but regulators are having a difficult time convincing drugmakers to develop them — largely because of unresolved commercial restraints. Antibiotics, especially against ...

I have been in the healthcare field for quite some time and luckily been pretty successful in determining when a small cap biotech has a product that is likely to progress in clinical trials or ...

Shares in Paratek were up almost a third in premarket trading this morning after Bloomberg said the company, gearing up to file a new antibiotic, is considering a sale. Last month, Paratek said a ...

BOSTON, June 25, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Could a small clinical-stage emerging pharmaceuticals ...

Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to perform badly. Zooming in on an example, the Paratek Pharmaceuticals, Inc.

BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ...

The pharma company announced a debt offering that has Wall Street scrambling. The notes will mature on May 1, 2024 -- sufficiently far in the future -- and are redeemable for approximately 63 shares ...

Paratek announced on Wednesday that it wanted to raise $50 million through a common stock offering. Investors learned on Thursday that the company succeeded in hitting that number by selling 3.2 ...

Transaction adds TYMLOS®to portfolio alongside NUZYRA®and XHANCE®and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 ...